Clinical trial · Observational
Everolimus Related Pneumonitis in MBC
Drug-related Pneumonitis During mTOR Inhibitor Therapy in Patients With Metastatic Breast Cancer: A Radiographic Patternbased Approach
NCT03730428CI-TRIAL-00046669completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Everolimus | — | UNRESOLVED | — |
| Pneumonitis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- pneumonitis group
- description
- Patients who developed drug-related pneumonitis after treated with everolims
- label
- non-pneumonitis group
- description
- Patients who didn't develop drug-related pneumonitis after treated with everolims
Primary outcomes (2)
- measure
- radiographic pattern
- timeFrame
- 2 months
- description
- Quantitive measure of lung CT
- measure
- PFS
- timeFrame
- 2 months
- description
- Progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with HR+，HER2- metastatic breast cancer 2. Treated with everolimus for at least one month in metastatic setting 3. With baseline and at least one follow-up chest CT during everolimus therapy. 4. Complete medical history Exclusion Criteria: 1. Incomplete medical history 2. Radiographic imaging unavailable
References
Publications (0)
Data not yet available
No reference posted for this study.